Pharmaceutical Department Residency Programs

General Information

 

Find out how to apply to any of the Pharmaceutical Department Residency Programs. If you can't find answers in How to Apply below or our Frequently Asked Questions, please contact us!

  1. Oncology-Pediatrics

    Jennifer L. Pauley, PharmD, BCPS, BCOP
    Mail Stop 150
    Phone: (901) 595-5440
    Email: jennifer.pauley@stjude.org

     

    Clinical Pharmacogenetics

    Kristine R. Crews, PharmD, FCCP, BCPS
    Mail Stop 313
    Phone: (901) 595-3338
    FAX: (901) 595-8869
    Email: kristine.crews@stjude.org

     

    Medication-Use Safety

    Jennifer Robertson, PharmD, BCPS
    Mail Stop 150
    Phone: (901) 595-6276
    FAX: (901) 595-3111
    Email: jennifer.robertson@stjude.org

    St. Jude Children's Research Hospital
    Pharmaceutical Department
    262 Danny Thomas Place
    Memphis, TN 38105-3678

  2. For any specific details and special requirements for acceptance for the various programs offered, please visit the residency description page for that program for details.

    To apply for any of the pharmaceutical department residency programs offered at St. Jude:

    While not required for candidacy, resident applicants are strongly encouraged to interview with St Jude staff at the Professional Placement Service (PPS/CareerPharm) at the ASHP Midyear Clinical Meeting.  

    Complete the following materials within PhORCAS:

    • Submit a copy of official school transcript
    • Letter of intent (please specify to which residency program you are applying)
    • Three (3) letters of reference

    Application deadline for all programs

    Second Monday in January

    Forward all residency application materials within PhORCAS to the PGY2 Residency Program Director as indicated below:

    Oncology-Pediatrics

    Jennifer L. Pauley, PharmD, BCPS, BCOP
    Mail Stop 150
    Phone: (901) 595-5440
    Email: jennifer.pauley@stjude.org

     

    Clinical Pharmacogenetics

    Kristine R. Crews, PharmD, FCCP, BCPS
    Mail Stop 313
    Phone: (901) 595-3338
    FAX: (901) 595-8869
    Email: kristine.crews@stjude.org

     

    Medication-Use Safety

    Jennifer Robertson, PharmD, BCPS
    Mail Stop 150
    Phone: (901) 595-6276
    FAX: (901) 595-3111
    Email: jennifer.robertson@stjude.org

    St. Jude Children's Research Hospital
    Pharmaceutical Department
    262 Danny Thomas Place
    Memphis, TN 38105-3678

     
  3. Examples of recent publications from St. Jude Pharmaceutical Department Residents

    Millisor VE, Roberts JK, et al. Derivation of new equations to estimate glomerular filtration rate in pediatric oncology patients. Pediatr Nehprol Jun 2 2017. Doi: 10.1007/200467-017-3693-5. [Epub ahead of print] PMID: 28573537

    Watts CS, Sciasci JN, Pauley JL, Panetta JC, et al. Prophylactic trimethoprim-sulfamethoxazole does not affect pharmacokinetics or pharmacodynamics of methotrexate. J Pediatr Hemaol Oncol Aug; 38(6):449-52, 2016. PMID: 28715509

    McDaniel RB, Burlison JD, Baker DK, Hasan M, Robertson J, Hartford C, Howard SC, Sablauer A, Hoffman JM. Alert dwell time: introduction of a measure to evaluate interruptive clinical decision support alerts. J Am Med Inform Assoc Oct 24, 2015. pii: ocv144. doi: 10.1093/jamia/ocv144. [Epub ahead of print] PMID: 26499101

    Gammal RS, Court MH, Haidar CE, Iwuchukwu OF, Gaur AH, Alvarellos M, Guillemette C, Lennox JL, Whirl-Carrillo M, Brummel S, Ratain MJ, Klein TE, Schackman BR, Caudle KE, Haas DW. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing. Clin Pharmacol Ther Sep 29, 2015. doi: 10.1002/cpt.269. [Epub ahead of print] PMID: 26417955

    Dunnenberger HM, et al. Preemptive Clinical Pharmacogenetics Implementation: Current Programs in Five United States Medical Centers. Annu Rev Pharmacol Toxicol 55:89-106, 2015. PMID: 25292429

    Bell GC, et al. Development and use of active clinical decision support for preemptive pharmacogenomics. J Am Med Inform Assoc 21:e93-9, 2014. PMID: 23978487

    Call RJ, et al. Adverse Drug Event Detection in Pediatric Oncology and Hematology Patients: Using Medication Triggers to Identify Patient Harm in a Specialized Pediatric Patient Population. J Pediatr Apr 2014 [Epub ahead of print]. PMID: 24768254

    Bernardo VA, et al. Posaconazole therapeutic drug monitoring in pediatric patients and young adults with cancer. Ann Pharmacother Jul-Aug;47(7-8):976-83, 2013. PMID: 23737511

    Hicks JK, et al. A Clinician-Driven Automated System for Integration of Pharmacogenetic Interpretations Into an Electronic Medical Record. Clin Pharmacol Ther 92(5):563-6, 2012. PMID: 22990750

    Christensen AM, et al. Resumption of high-dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients. Cancer Sep 1;118(17):4321-30, 2012. PMID: 22252903